Background: Epoetin (EPO) administration reduces the need for transfusion. Identifying patients at high risk of anemia requiring red blood cell (RBC) transfusion is needed. This multicentric phase III trial tested epoetin a (EPOa) administration according to our risk model on the basis of three clinical parameters: hemoglobin (Hb) <12 g/dl, lymphocytes £700/ll, and/or performance status (PS) >1.
introduction
Anemia is a particularly frequent complication of cancer, due to neoplastic disease, anticancer therapies, and associated conditions of the patient. Anemia results in decreased functional capacity and quality of life (QoL) [1] . Severe anemia can be treated with red blood cell (RBC) transfusion, but this procedure is associated with risks of transmission of infection and allo-immunization, reduced QoL, and increased costs [2] . Clinical studies in patients with cancer and anemia receiving chemotherapy have shown that epoetin (EPO) significantly increases hemoglobin (Hb) levels, decreases transfusion requirements, improves levels of energy and activity, and decreases fatigue [3, 4] . In 1993, the Food and Drug Administration (FDA) approved epoetin a (EPOa) treatment of patients with cancer on the basis of pooled data from six randomized, double-blind, placebo-controlled trials that included patients with various types of cancer [2, 5] . The approval focused on the effectiveness of EPOa in reducing the number of transfusions required to treat chemotherapyinduced anemia. Decreased fatigue associated with EPO is well established, clinically meaningful [3] , and significantly correlated with increased Hb [2, 4, 6] . However, prophylactic erythropoietin treatment is expensive [7] , and several studies have reported a possible detrimental effect of EPO on progression-free survival (PFS) or overall survival (OS) in cancer patients [8] [9] [10] [11] [12] . Similarly, a recent USA FDA analysis has not found robust data confirming the beneficial impact of erythropoietin stimulating agent (ESA) on QoL [13] [14] [15] .
original article *Correspondence to: Dr I. Ray-Coquard, Centre Lé on Bé rard, 28 rue Laennec, 69008 Lyon, France. Tel: +33-478782888; Fax: +33-478782716; E-mail: ray@lyon.fnclcc.fr
Factors influencing the pharmacoeconomics of prophylactic EPO treatment include the identification of early predictors of response to erythropoietin, optimal dose and schedule of treatment, safety of EPO, as well as costs associated with RBC transfusion and with the administration of EPO to patients at high risk for this complication. It is therefore important to identify patients in whom the preventive use of erythropoietin (Hb level >10 g/dl) could be pertinent.
We have previously reported a simple risk model on the basis of three factors: Hb level, lymphocyte count (Ly), and performance status (PS). The model has enabled us to identify subgroups of patients at different risks for RBC transfusion [16] . In the first study published in 1999, 30% of patients with Hb <12 g/dl and at least one of the other two risk factors (lymphopenia £700/ll and PS >1) required RBC transfusion within 31 days following day 1 of chemotherapy and 65% in the following 3 months. Importantly, 92%-100% of all transfused patients belonged to the two highest risk groups [16] . This model was later validated in the pediatric population [17] .
Accurate identification of these patients remains a major issue: whereas a recent report has indicated that EPO improves the QoL of patients with chemotherapy [6] regardless of disease type and response to chemotherapy, some doubts have arisen regarding its impact on survival and risk/benefit ratio [12] [13] [14] as others did not published the detrimental effect of EPO [18] . In view of recent results indicating a negative impact of erythropoietin on the survival of patients with cancer, proper selection of candidate patients is essential [10] .
We proposed to use this model to identify patients for whom primary prophylactic administration of erythropoietin is clinically justified. The present randomized phase III study was undertaken to determine whether EPO should be used specifically in the subgroup of patients at high risk of transfusion-dependent anemia identified by the ELYPSE model and to evaluate the clinical benefit and safety of prophylactic treatment with erythropoietin in this subgroup.
materials and methods objectives
This phase III trial aimed to identify the benefit of EPOa for primary prophylaxis of severe anemia in high-risk patients (>30% RBC transfusions) versus no EPOa according to the ELYPSE risk model previously described by our group and on the basis of three clinical parameters: Hb <12g/dl, Ly £700/ll, and/or PS >1 [16] .
This risk model could be used to identify patients for whom primary prophylactic administration of erythropoietin would be clinically justified and well tolerated [19] [20] [21] . The primary end point of the study was to determine the impact of EPOa on the number of RBC transfusions in chemotherapy-treated cancer patients with high risk of severe anemia requiring RBC transfusion, whatever the line and the type of chemotherapy. Secondary end points included change in Hb level from baseline to study completion, OS, safety, change in QoL measured by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire, differences in the nadir of RBCs after four computed tomography (CT) courses, and time to disease progression.
study design
This randomized, controlled, open, multicenter study was conducted in nine sites in France from September 2000 to January 2005. The study protocol and amendments were reviewed by an independent ethics committee, and the study was conducted in accordance with the Declaration of Helsinki. All patients provided written consent to participate.
Anemic patients ‡18 years with solid tumors or hematologic cancer requiring CT were randomized to receive standard chemotherapy either with EPOa or without EPOa. Randomization was centralized and stratified according to the participating centers and the number of prognostic factors for severe transfusion-dependent anemia, with two versus three of the following criteria: Hb level at day 0 <12 g/dl, Ly <700/ll, and PS >1. Patients in arm 1 received s.c. injections of EPOa at the dose of 150 UI/kg/ TIW, whereas patients from arm 2 were just followed. patients inclusion criteria. Eligible patients were those with histologically documented cancer necessitating chemotherapy. Other requirements included age >18 years, Hb <12 g/dl at day 1 of chemotherapy cycle, Ly £700/ll or/and PS >1 at day 1, disease progression requiring chemotherapy, negative HIV test in patients with non-Hodgkin's lymphoma, chemotherapy not requiring hematopoietic stem-cell support, chemotherapy planned for at least 3 months and inclusion during first or second course of chemotherapy (whatever the line of treatment). Approval from regulatory authorities and ethics committees was obtained, and all patients gave written informed consent before taking part in the study. exclusion criteria. Exclusion criteria were systematic administration of EPO during chemotherapy, uncontrolled hypertension (i.e. diastolic blood pressure >95 mmHg), patient refusal, anemia in cancer patients not receiving chemotherapy, and history of nervous or psychiatric disorder that would preclude informed consent or compliance. Patients were also excluded if they had anemia resulting from factors other than cancer or its treatment (e.g. hemolysis, gastrointestinal bleeding), untreated folate or vitamin B 12 deficiency, pregnancy, history of thrombovascular events in the preceding 6 months, current dose intensification chemotherapy for bone marrow, or stem-cell transplant in the preceding 8 weeks. treatments study treatment. Eligible patients were randomly assigned within 5 days before the first chemotherapy cycle to receive EPOa 150 UI/kg s.c. TIW, or no EPOa, for 12 weeks. Hb level and Ly were then monitored weekly for 4 weeks to determine whether EPOa dose adjustments were necessary, then every 3-4 weeks for the remainder of the treatment period. During study drug administration, Hb was to be maintained at 12 g/dl. EPOa dose adjustments were permitted. If Hb increased >2 g/dl in a month, EPOa was decreased to 75% of the original dose to maintain the monthly rate of Hb increase <2 g/dl; if after receiving the initial 4 weekly doses of EPOa, Hb was <10.5 g/dl with <1 g/dl decrease in the previous 4 weeks, and reticulocyte count <40 000 cells/ll, EPOa was increased to 60 000 UI weekly. If Hb level increased beyond 12 g/dl, EPOa was interrupted until Hb level returned to <12 g/dl. At the end of the 12-week study period, all patients (including patients in arm 2) had the option to receive EPOa in an open-label extension phase. associated treatments. Oral iron supplementation was administered to support erythropoiesis in patients with iron deficiency since no information on the improved efficacy of i.v. iron treatment was available at the initiation of the trial. Granulocyte growth factors could be used in primary or secondary prophylaxis as recommended by American Society of Clinical Oncology (ASCO) and French Federation of Cancer Center guidelines [20, 22] .
assessments and efficacy criteria
In this study, the primary end point was the incidence of severe anemia requiring RBC transfusion [16] : grade III anemia (Hb <8 g/dl) or grade II anemia (Hb <10 g/dl and ‡8 g/dl) in patients with grade III symptomatic original article Annals of Oncology cardiopathy, tachycardia (>100 beats/min), symptomatic angina with electric signs (modification of ST segment), grade III dyspnea, symptomatic pneumopathy (PaO2, 50-64; diffusion of carboxy oxygen, 54%-40%; volume capacity, 54%-40%), and grade III asthenia.
Before random assignment, patients were screened for demographic data, history of malignancy, medical history, complete physical examination, clinical laboratory tests (complete blood count, serum chemistry, iron status, albumin, lactate dehydrogenase, C reactive protein (CRP), etc.), current therapy, and Eastern Cooperative Oncology Group PS. QoL was evaluated at baseline using the EORTC QLQ-C30 questionnaire, then every month. At the end of each chemotherapy cycle, the following were recorded: vital signs, study drug administration, RBC transfusion use, chemotherapy details, and adverse events. After the last chemotherapy cycle or at disease progression, whichever occurred first, and at study completion (6 months after end of treatment or early withdrawal), all assessments were repeated. Some data were collected beyond withdrawal; although limited, this evaluation included a determination of whether the patient was still alive at 6 months after completion of the study or, if not, the date of death, even for patients who withdrew early.
Safety was evaluated by adverse event reporting and clinical laboratory tests according to the schedule previously outlined. Any clinically significant abnormalities at study end were observed until resolution or until clinically stable. Thrombovascular events were compiled by medical monitor, on the basis of WHO Adverse Reaction Terms 97 Q4. No systematic specific exam was carried out to evaluate the risk; only reported events and/or abnormal results of tests ordered by investigators were taken into account.
statistical analysis
In previously published cohorts of patients, the incidence of severe anemia requiring RBC transfusion was 30%. The planned sample size in our study was 216 patients in order to detect a 15% difference in RBC transfusions with a power of 80% and a one-sided significance level of 5%. The study was powered to detect a hypothesized decrease from 30% to 15% with EPO. The analysis was made on an intention-to-treat basis and carried out using the SAS software (version 8.02).
Groups were compared by descriptive statistical analysis, and differences were tested by the usual tests. OS was the time interval from randomization to date of death or last follow-up. Survival estimates were calculated by the method of Kaplan-Meier, and differences were assessed by the log-rank test. Median follow-up was calculated using reverse Kaplan-Meier estimation [23] . Parameters predictive of response to EPOa were assessed in a multivariate analysis using logistic regression. A backward selection procedure was used to build the final model, with statistical significance at 0.1 in the univariate analysis. Safety variables were analyzed using the safety population (all randomly assigned patients with at least one safety assessment). QoL data were assessed according to the EORTC QLQ-C30 scoring manual. Global QoL scores were compared between the two arms for each chemotherapy cycle, and variations from baseline were calculated for each patient and compared between arms after stratification into three levels on the assumption that a 10-point disparity represented a clinically pertinent differential.
results
Two hundred and eighteen patients with cancer necessitating chemotherapy were enrolled and then randomly assigned to receive EPOa (110 patients) or no EPOa (108 patients). Five patients (2.3%) were enrolled but did not receive chemotherapy (four died before the beginning of treatment and one received no chemotherapy); 213 patients were therefore assessable for primary criteria (rate of RBC transfusions) and toxicity.
Protocol deviations were reported in five patients (2%): two began treatment with the study drug while their Ly was >700/ll and their PS <2, one withdrew informed consent, and two were not included during the first or second courses of chemotherapy.
patient characteristics
Patients' clinical and biological characteristics are described in Tables 1 and 2 . Patient distribution was well balanced between the two groups of treatment. In total, 85% of the patients were metastatic at inclusion in the study and the majority (75%) was in the stratum corresponding to two prognostic factors.
incidence of severe anemia requiring RBC transfusion Table 3 We investigated prognostic factors for 'response to EPO', defined as no RBC transfusion during the whole study period, for patients included in the EPOa arm; 108 patients were evaluated in univariate analysis. Seven parameters were found significant: previous history of RBC transfusion, cardiopathy, Hb level, high hematocrit level, low ferritin level, high albumin level, and low CRP level. Eighty-four patients were included in the multivariate analysis. The final model showed that no previous history of RBC transfusion [odds ratio (OR): 0.36; 95% CI: 0.135-0.978] and Hb level >10 g/dl at baseline (OR: 0.27; 95% CI: 0.09-0.84) were independent risk factors for response to EPO.
survival
With a median follow-up of 12 months (95% CI: 12-12.4) and a median survival of 6.57 months (95% CI: 5.4-8.3) for the whole population, no significant difference in OS was observed between the two arms ( Figure 1 ). The median survival duration was 7.6 months (95% CI: 5.3-10.4) for patients in the EPOa arm and 6.0 months (95% CI: 5.0-8.0) for patients in arm 2 (P = 0.148) (Figure 1) . A majority (73%) of patients had died at the time of final analysis. In univariate analysis, only Ly was found to be correlated to OS, with a median OS of 4.2 months (95% CI: 3.0-5.5) for patients with £700/ll lymphocytes versus 8.3 months (95% CI: 6.6-10.4) otherwise. This result was consistent with our previous observations [24] . Similarly, patients with two prognostic factors had a significantly better OS than patients with three factors (median 8.3 versus 3.6 months, P < 0.0001; hazard ratio: 2.36, 95% CI: 1.7-3.3) (Figure 2 ). However, Hb counts <10 versus ‡10 (median 6.2 versus 7.1 months, P = 0.9), PS 0 or 1 versus >1 (median 13.1 versus 6.5, P = 0.18), metastatic carcinoma versus nonHodgkin's malignant lymphoma versus metastatic sarcoma (median 6.3 versus 8.4 versus 7.4, P = 0.34), or first-line treatment versus first relapse versus more than two relapses (median 7.0 versus 7.9 versus 5.3, P = 0.08) were not found to Primary causes of death within 12 months determined by the investigator were disease progression (27% for EPOa versus 22% for no treatment), chemotherapy toxicity (1.7% for EPOa versus 0.2% for no treatment), and thrombovascular events (1.3% for EPOa versus 0.6% for no treatment).
toxicity
The overall incidence of serious adverse events, including deaths, was 50% in the EPOa group and 46.7% in arm 2 (P = 0.63). In the EPOa group, 4.6% of serious adverse events were considered related to the study drug versus 2.9% in arm 2 (P = 0.72). The overall incidence of thrombovascular events was similar in the EPOa group (4.5%) and in arm 2 (3.7%). Table 4 shows serious adverse events in each group of patients; no significant difference was reported. In both arms, 20 patients died of toxicity. No difference in hematological toxic effects was 
quality of life
Only 54% of the questionnaires (118) were available for QoL evaluation, 57% in arm 1 (n = 63) and 51% in arm 2 (n = 55).
Significant differences in favor of the EPOa arm were noted for QoL scores at inclusion (P = 0.048). However, no statistically detectable differences were noted during the study period, whatever the date of evaluation (at 1, 2, 3, or 4 months or at the end of the study, all P > 0.2). Global scores remained stable or slightly increased in both arms during the entire study.
discussion
The preventive treatment of anemia with EPO in cancer patients not only enables to reduce transfusions and to improve Annals of Oncology original article fatigue but has also been associated with an increased risk of relapse in some of the phase III clinical trials [8] [9] [10] 25] . Assessing the risk of anemia would therefore be useful in order to propose prophylactic treatment only to patients at high risk. In the ELYPSE studies [16, 17] , we identified a group of patients encompassing 92% of the whole adult transfused population (67% in the pediatric population) treated in a cancer center with a >30% risk of experiencing anemia requiring transfusion within 30 days [11, 12] .
However, whether patients at high risk according to this model would benefit from prophylactic EPO treatment remained unknown.
The purpose of this randomized trial was therefore to confirm the activity of EPO in the group of high-risk patients identified in previous ELYPSE studies [16] . The present study conducted in a prospectively collected cohort of patients confirms the validity of the risk model for identifying a group at high risk for RBC transfusion. Indeed, in this cohort of moderately anemic patients (median baseline Hb levels of 10.1 g/dl), 47% were transfused, with an increased risk for patients with both lymphopenia <700 and performance score above one, in agreement with the model [11] . EPOa administration significantly decreased the risk for RBC transfusion by 38%. Interestingly, as previously reported, we did not find any difference in terms of response to EPOa according to disease type, number of relapses, type of chemotherapy regimen, and number of lines of treatment.
Although the criteria of inclusion in this study delineated in 2000 were not consistent with international guidelines for treatment with ESA [14, 26] , the benefit of EPO was statistically significant for these patients at high risk for RBC transfusion, and no detrimental effect was observed in the statistical analysis. Since 2003, major concerns have emerged about the possible detrimental effect of EPO on OS and PFS in randomized phase III trials comparing EPO versus RBC transfusion. The results of the present randomized study focusing exclusively on a population of cancer patients on chemotherapy and at high risk for RBC transfusion do not support this hypothesis: the prophylactic use of EPOa did not significantly affect OS or PFS in our patients, either in the whole cohort or in subgroups with localized disease, metastatic disease, or different histological subtypes. However, a majority of patients from this study had advanced disease with a median survivorship of only 7 months, which could explain the absence of difference in survival between the two groups of patients. For patients with localized disease, no detrimental effect was noted between the two arms, but the number of patients was small (n = 28). Interestingly, the high risk of RBC transfusion mostly applied to patients with advanced disease or in relapse. Similarly, no differences in PFS were observed between the two arms in the different tumor subtypes. Since the statistical analysis stratified patients according to tumor subtype, no clear interpretation, subtype by subtype, could be elaborated. However, because of the small number of patients in each subgroup, the absence of differences cannot be completely ruled out. Finally, in this cohort of moderately anemic patients (Hb <12 g/dl), no difference in the rate of thrombovascular events was detected between the two arms. Per-protocol EPOa treatment was interrupted if Hb levels increased >12 g/dl. The increased risk of thromboembolic events had actually been demonstrated in two phase III clinical trials reported in 2003 [8, 10] which unequivocally showed an increased risk of death or cardiovascular or thromboembolic events among patients treated with erythropoiesis-stimulating agents for normalization of Hb levels (13.5 g/dl or higher), as compared with patients achieving levels in the subnormal range (10.5-11.5 g/dl) [27] [28] [29] .
As indicated in a previous report by Henke et al. [11] , the worse prognosis observed in the EPO treatment group in his study could be explained by EPO receptor expression on cancer cells. Even so, we observed no impact of EPO treatment on survival and we are currently evaluating the expression of EPO receptor on tumor blocks from the patients treated in the present trial. In this series, no QoL difference was found between the subgroup receiving EPOa and other patients. This could be due to the limited number of questionnaires available for evaluation both at baseline and throughout the study period: only 54% of the patients were evaluated, which seems insufficient, in this limited series of patients, to show any improvement. Indeed, after the first course of chemotherapy, 50% of the patients in the EPOa arm were scored as improved by treatment according to the QLQC30 scale versus only 21.4% in the control arm; these data were, however, collected unblinded.
In conclusion, this randomized trial confirms the validity of the previously described risk model, with the identification of a group of patients at high risk for anemia requiring RBC transfusion (patients receiving chemotherapy with Hb level <12, PS >1, and/or Ly £700/ll) who represent >90% of the patients who will need RBC transfusion. It also demonstrates that, in this selected group, primary prophylaxis with EPOa reduces the need for transfusion without a priori negative impact on survival. Finally, lymphopenia has a major impact on OS in this series, thus confirming previous observations [17, 24, [30] [31] [32] [33] [34] [35] . In the patients selected with this risk model, EPO administration seems safe and substantially reduces the risk for RBC transfusions. 
